Invesaro

Stocks Health care BSX

NYSE · Health care

Boston Scientific Corp (BSX)

Boston Scientific Corp brought in $21B of revenue over the twelve months to June 30, 2026, up 13.5% from a year earlier. Net income was $3.7B, a net margin of 17.5%. Operating cash flow minus capital spending left $3.7B of free cash flow in fiscal 2025. At June 30, 2026 it held $539M in cash against $10.9B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 3, 2026.

Price
$43.92
-1.70% on the day · September 25, 2026
52-week range $42.20 to $105.65
Market cap
$63.7B
Revenue (last 12 months)
$21B
+13.5% year on year
Net margin
17.5%
P/E
22.6
on FY2025 diluted EPS

What Boston Scientific Corp does

Boston Scientific develops, manufactures, and markets medical devices used in interventional medical specialties. Its products include pacemakers, defibrillators, stents, catheters, and endoscopy tools, which are purchased by hospitals, clinics, and physicians worldwide. Its shares trade on NYSE under the ticker BSX.

Revenue and profit by year

Revenue
FY18: $9.8B $9.8B FY18FY19: $10.7B $10.7B FY19FY20: $9.9B $9.9B FY20FY21: $11.9B $11.9B FY21FY22: $12.7B $12.7B FY22FY23: $14.2B $14.2B FY23FY24: $16.7B $16.7B FY24FY25: $20.1B $20.1B FY25
Net income
FY18: $1.7B $1.7B FY18FY19: $4.7B $4.7B FY19FY20: -$115M -$115M FY20FY21: $985M $985M FY21FY22: $642M $642M FY22FY23: $1.6B $1.6B FY23FY24: $1.9B $1.9B FY24FY25: $2.9B $2.9B FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$20.1B$3.6B$2.9B$1.94$3.7B
2024$16.7B$2.6B$1.9B$1.25$2.6B
2023$14.2B$2.3B$1.6B$1.07$1.8B
2022$12.7B$1.6B$642M$0.45$938M
2021$11.9B$1.2B$985M$0.69$1.3B
2020$9.9B-$80M-$115M-$0.08$1.1B

Latest SEC filings

What Boston Scientific Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 23, 2026
  2. September 8, 2026
  3. August 26, 2026
  4. August 6, 2026
  5. August 3, 2026
    Quarterly report 10-Q · period to June 30, 2026
  6. July 29, 2026
  7. July 27, 2026
  8. June 24, 2026
  9. May 21, 2026
  10. May 18, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 3, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about BSX

What does Boston Scientific Corp do?

Boston Scientific develops, manufactures, and markets medical devices used in interventional medical specialties. Its products include pacemakers, defibrillators, stents, catheters, and endoscopy tools, which are purchased by hospitals, clinics, and physicians worldwide. Its shares trade on NYSE under the ticker BSX.

Is Boston Scientific Corp profitable?

Yes. Over the twelve months to June 30, 2026 it reported net income of $3.7B on revenue of $21B, a net margin of 17.5%.

How much revenue does Boston Scientific Corp make?

Over the twelve months to June 30, 2026 Boston Scientific Corp reported revenue of $21B. That is 13.5% more than a year earlier.

When did Boston Scientific Corp last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 3, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the executive or director change from September 23, 2026.

Similar companies

Follow BSX

Get an email when Boston Scientific Corp files with the SEC: results, executive changes, material agreements and annual reports.

Follow BSX: get an email when it files

Where the numbers come from

Financial figures are the values Boston Scientific Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.